• Profile
Close

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

Gynecologic Oncology Aug 16, 2019

Wade KNS, Brady MF, Thai T, et al. - A prospective phase 3 trial (GOG 218) was undertaken to assess the link between measurements of adiposity (BMI, surface fat area, and visceral fat area [VFA]) and prognosis for oncologic outcomes among patients treated with chemotherapy, with or without bevacizumab (BEV), an anti-angiogenic agent. The ultimate goal was to find whether adiposity interferes with the activity of BEV. Researchers analyzed computed tomography scans taken prior to treatment for 1,538 GOG 218 participants. Findings revealed a strong correlation between measures of adiposity. However, the effectiveness of BEV was not predicted by measures of adiposity. In this study, VFA was identified as a weak prognostic factor.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay